The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 19, 2017
Filed:
Feb. 12, 2016
Applicant:
Therabron Therapeutics, Inc., Rockville, MD (US);
Inventor:
Aprile L. Pilon-Clayton, Germantown, MD (US);
Assignee:
Therabron Therapeutics, Inc., Rockville, MD (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 9/10 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); C07K 14/435 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 9/0043 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/186 (2013.01); C07K 14/435 (2013.01); C07K 14/47 (2013.01);
Abstract
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.